Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ariela Noy

Showing results (91-100 of 138) with videos related to

Pageof 14
Sort By:
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Cancers|March 29, 2023
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical SettingSerena Zheng, Kanika Gupta, Piyush Goyal, et al.
Blood Cancer Journal|June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapseSabela Bobillo, Erel Joffe, David Sermer, et al.
Blood Advances|July 30, 2020
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphomaDavid Sermer, Sabela Bobillo, Ahmet Dogan, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
The Lancet. Oncology|February 17, 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyAlison J Moskowitz, Heiko Schöder, Joachim Yahalom, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Leukemia & Lymphoma|July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysisEfrat Luttwak, Edith Tama Robin, Esther Drill, et al.
Haematologica|November 27, 2025
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphomaErel Joffe, Manik Uppal, Serena Zheng, et al.
Pageof 14

Showing results (91-100 of 138) with videos related to

Sort By:
Pageof 14
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Cancers|March 29, 2023
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical SettingSerena Zheng, Kanika Gupta, Piyush Goyal, et al.
Blood Cancer Journal|June 17, 2021
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapseSabela Bobillo, Erel Joffe, David Sermer, et al.
Blood Advances|July 30, 2020
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphomaDavid Sermer, Sabela Bobillo, Ahmet Dogan, et al.
Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.
The Lancet. Oncology|February 17, 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyAlison J Moskowitz, Heiko Schöder, Joachim Yahalom, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Leukemia & Lymphoma|July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysisEfrat Luttwak, Edith Tama Robin, Esther Drill, et al.
Haematologica|November 27, 2025
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphomaErel Joffe, Manik Uppal, Serena Zheng, et al.
Pageof 14